Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,034,116
  • Shares Outstanding, K 177,907
  • Annual Sales, $ 693,400 K
  • Annual Income, $ -705,810 K
  • EBIT $ -242 M
  • EBITDA $ -198 M
  • 60-Month Beta 5.22
  • Price/Sales 8.16
  • Price/Cash Flow N/A
  • Price/Book 19.58

Options Overview Details

View History
  • Implied Volatility 81.45% (+4.03%)
  • Historical Volatility 59.44%
  • IV Percentile 54%
  • IV Rank 28.38%
  • IV High 133.93% on 04/08/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 7) 4.24 (8.35%)
  • Put/Call Vol Ratio 0.99
  • Today's Volume 21,236
  • Volume Avg (30-Day) 21,855
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 266,383
  • Open Int (30-Day) 269,700
  • Expected Range 46.54 to 55.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.25
  • Low Estimate -0.33
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.40 +2.79%
on 02/12/26
73.26 -30.69%
on 01/15/26
-18.48 (-26.68%)
since 01/12/26
3-Month
49.40 +2.79%
on 02/12/26
79.96 -36.49%
on 11/26/25
-20.32 (-28.58%)
since 11/12/25
52-Week
36.22 +40.20%
on 04/09/25
104.32 -51.32%
on 10/09/25
-23.10 (-31.27%)
since 02/12/25

Most Recent Stories

More News
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a collaboration with Median Technologies (EPA: ALMDT) to bring Median’s proprietary...

TEM : 50.78 (-5.28%)
As Crypto Prices Plunge, Cathie Wood Is Selling This 1 Bitcoin Stock

The crypto price crash has led to continued trouble for crypto stocks.

BLSH : 31.71 (-0.53%)
TER : 311.03 (-3.24%)
GOOG : 309.37 (-0.63%)
GOOGL : 309.00 (-0.63%)
^ETHUSD : 1,967.119 (+2.29%)
AVGO : 331.17 (-3.38%)
TTD : 26.14 (-4.00%)
CRCL : 56.63 (-2.13%)
^BTCUSDC : 67,112.09 (+2.02%)
COIN : 141.09 (-7.90%)
ARKK : 68.45 (-3.41%)
CRWV : 95.70 (+0.58%)
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24

Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2025 on Tuesday, February...

TEM : 50.78 (-5.28%)
Ambry’s Contributions to MAVEs Support Thousands of Patient Reclassifications and Expand to New Genes

New study published in Nature Communications builds on Ambry’s contributions to MAVE research to deepen understanding of PALB2 and its role in hereditary...

TEM : 50.78 (-5.28%)
Ambry Genetics Announces One Millionth Test Leveraging RNA to Improve Diagnostic Accuracy and Yield

Milestone highlights growing adoption of DNA and RNA-informed diagnostics for hereditary cancer and rare disease

TEM : 50.78 (-5.28%)
Cathie Wood Just Bet $26 Million on Broadcom Stock. Should You Buy AVGO Too?

Cathie Wood bets on Broadcom while shorting major market names in a week of activity.

BLSH : 31.71 (-0.53%)
ARKX : 30.95 (-1.05%)
NFLX : 75.86 (-4.72%)
META : 649.81 (-2.82%)
ROKU : 82.93 (-5.64%)
TXG : 17.51 (-8.56%)
GTLB : 29.58 (-1.47%)
AVGO : 331.17 (-3.38%)
TWST : 47.66 (-3.99%)
ILMN : 114.44 (-1.67%)
CRCL : 56.63 (-2.13%)
WRD : 7.46 (-1.19%)
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune...

TEM : 50.78 (-5.28%)
Pelosi’s Bullish 2026 Buy List: AI, Power & Dividends

The famous congressional portfolio is rotating capital into dividend-paying financial stocks while doubling down on artificial intelligence and energy.

AB : 40.52 (+0.60%)
NVDA : 186.94 (-1.64%)
GOOGL : 309.00 (-0.63%)
AAPL : 261.73 (-5.00%)
VST : 163.10 (+1.84%)
TEM : 50.78 (-5.28%)
AMZN : 199.60 (-2.20%)
Tempus Announces the Launch of Paige Predict

Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital pathology

TEM : 50.78 (-5.28%)
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology

Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation’s premier academic medical centers, today announced a multi-year strategic collaboration...

TEM : 50.78 (-5.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 57.90
2nd Resistance Point 55.93
1st Resistance Point 53.35
Last Price 50.78
1st Support Level 48.80
2nd Support Level 46.83
3rd Support Level 44.25

See More

52-Week High 104.32
Fibonacci 61.8% 78.31
Fibonacci 50% 70.27
Fibonacci 38.2% 62.23
Last Price 50.78
52-Week Low 36.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar